Views
4 years ago

118 - MF Iveli, V Ferreyra - Noviembre 2019

  • Text
  • Uruguay
  • Eficacia
  • Trastorno
  • Dosis
  • Fluoxetina
  • Riesgo
  • Irss
  • Antidepresivos
  • Adolescentes
  • Infantojuvenil
  • Tratamiento
Tratamiento de la depresión en niños y adolescentes

Dra. María Florencia

Dra. María Florencia Iveli, Dra. Valeria Ferreyra Referencias bibliográficas • 1. Organización Mundial de la Salud, 2018. https://www.who.int/es/news-room/fact-sheets/ detail/depression. • 2. Cipriani A, Zhou X, Del Giovane C, Hetrick SE, Qin B, Whittington C, Coghill D, Zhang Y, Hazell P, Leucht S, Cuijpers P, Pu J, Cohen D, Ravindran AV, Liu Y, Michael KD, YangL, Liu L, Xie P. Comparative efficacy and tolerability of antidepressants formajor depressive disorder in children and adolescents: a network meta-analysis. The Lancet 2016; 388: 881-890. • 3. Dolle K, Schulte-Körne G. The treatment of depressive disorders in children and adolescents. DtschArztebl Int 2013; 110 (50):854- 860. • 4. Brown J, Cohen P, Johnson JG, Smailes EM. Childhood abuse and neglect: specificity of effects on adolescents and Young adult depression and suicidability. J Am Acad Child Adolesc Psychiatry 1999; 38: 1490-1496. • 5. Qin B, Zahang Y, Zhou X, Cheng P, Liu Y, Chen J, Fu Y, Lou Q, Xie P. Selective serotonine reuptake inhibitors versus tricyclic antidepressants in Young patients: a meta-analysis of efficacy and acceptability 2014; 36: 1087-1095. • 6. Cheung AH, Zuckerbrot RA, Jensen PS, Laraque D, Stein REK. Guidelines for Adolescent Depression in Primary Care (GLADPC): Part II. Treatment and Ongoing Management. Pediatrics.2018;141(3): e20174082. • 7. Clark MS, Jansen KL, Cloy A. Treatment of childhood and adolescent depression. American Family Physician 2012; 38 (5) 442-448. • 8. Regier DA, Narrow WE, Clarke DE, Kraemer HC, Kuramoto SJ, Kuhl EA, Kupfer DJ. DSM-5 field trials in the United States and Canada, Part II: test-retest reliability of selected categorical diagnoses. Am J of Psychiatry 2013: 170 (1) 59-70. • 9. Garland EJ, Kutcher S, Virani A, Elbe D. Update of the use of SSRIs and SNRIs with children and adolescents in clinical practice. J Can Acad Child Adolesc Psychiatry 2016; 25 (1) 4-10. • 10. Dunn V and Goodyler IM. Longitudinal investigation into childhood and adolescence onset depression: psychiatric outcome in early adulthood. Br J Psychiatry 2006; 188: 216-222. • 11. Curry J, Silva S, Rohde P, Ginsburg G, Kratochvil C, Simons A, Kirchner J, May D, Kennard B, Mayes T, Feeny N, Albano AM, Lavanier S, Reinecke M, Jacobs R, Becker-Weidman E, Weller E, Emslie G, Walkup J, Kastelic E, Burns B, Wells K, March J. Recovery and recurrence following treatment for adolescent major depression. Archives of General Psychiatry 2011; 68: 263-270. • 12. Rey JM, Bella-Awusah TT, Jing L. Depresión en niños y adolescentes. (Prieto-Tagle MF, ed.). En Rey JM (ed), Manual de Salud Mental Infantil y Adolescente de la IACAPAP. Ginebra: Asociación Internacional de Psiquiatría del Niño y el Adolescente y Profesiones Afines 2017. • 13. Ryan ND. Child and adolescent depression: short term treatment effectiveness and long term opportunities. Int J methodes Psychiatr Res 2003; 12 (1): 44-53. • 14. Treatment for Adolescents with Depression Study (TADS) Team. The Treatment for Adolescents with Depression Study (TADS): outcomes over 1 year of naturalistic follow-up. American Journal of Psychiatry 2009; 166(10):1141- 1149. • 15. Morales Carpi C, Estañ L, Rubio E, Lurbe E, Morales Olivas FJ. Drug utilization and off label drug use among Spanish emergency room pediatric patients. Eur J Clin Pharmacol 2010; 66:315-320. • 16. Palermo A, Bissuel R, Renaud N, Durrieu G, Escourrou B, Oustric S. Off label prescribing in pediatric outpatients. 2015; 135: 49-58. • 17. MacQueen GM, Frey BN, Ismail Z, Jaworska N, Steiner M, Van Lieshout RJ, Kennedy SH, Lam RW, Milev RV, Parikh SV, Ravindran AV and the CANMAT Depression Work Group. Canadian Network for Mood and Anxiety Treatments (CAN- MAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 6. Special Populations: Youth, Women, and the Elderly. • 18. Whittington CJ, Kendall T, Fonagy P, Cottrell D, Cotgrove A, Boddington E. Selective serotonine reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. The Lancet 2004; 363: 1341-1345. • 19. Lu CY, Zhang F, Lakoma MD, Madden JM, Rusinak D, Penfold RB, Simon G, Ahmedan BK Clarke G, Hunkeler EM, Waitzfelder B, Owen-Smith A, Raebel MA, Rossom R, Coleman KJ, Soumerai SB.Changes in antidepressant useby young people and suicidal behavior after FDA warnings and media coverage: quasi-experimental study. BMJ 2014; 348: g3596. • 20. Wijlaars LPMM, Nazareth I, Whitaker HJ, Evans SJW, Petersen I. Suicide related events in Young people following prescription of SSRIs and other antidepressants: a self controlled case series análisis. BMJ 2013;3 e 003247. • 21. Cooper WO, Callahan ST, Shintani A, Fuchs C, Shelton R, Dudley JA, Graves A, Ray WA. Antidepressants and suicide attemps in children. Pediatrics 2014; 133: 204-210. • 22. Cheung K, Aarts N, Noordam R, Blijderveen JC, Sturkenboom MC, Ruiter R, Visser LE, Stricker BH. Antidepressant use and risk of suicide: a population based cohort study. J of affective disorders 2015; 174: 479-484. • 23. Gordon M, Melvin G. Selective serotonin re-uptake inhibitors. A revew of the side effects. Australian family physician 2013; 42 (9):620-623. • 24. Taurines R, Gerlach M, Warnke A, Thome J, Wewetzer. Pharmacoterapy in depressed children and adolescents. The world J of Biological Psychiatry 2011; 12: 11-15. • 25. Atkinson S, Lubaczewski S, Ramaker S, England R, Wajsbrot DB, Abbas R, Findling RL. Desvenlafaxine versus placebo in the treatment od child and adolescents with major depressive disorder. J ofchild and adolescent psychopharmacology 2018; 28: 54-65. • 26. Hopkins K, Croslan P, Elliott N, Bewley S. Diagnosis and management of depression in children and young people: summary of updated NICE guidance. BMJ 2015;350:h824. 8 // EDITORIAL SCIENS

Biblioteca

Av. García del Río 2585 Piso 12 A - C.A.B.A
+54 11 2092 1646 | info@sciens.com.ar

Editorial Sciens, Todos los Derechos Reservados 2015